{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:59Z","timestamp":1786681859946,"version":"build-2736575974"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in type 2 diabetes mellitus (T2DM) and amplifies cardiovascular and metabolic burden. Elevated low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cerebrovascular stenosis, and MASLD-mediated hepatic lipid dysregulation is closely linked to LDL-C metabolism. One-hour postload plasma glucose (1h-PG) reflects early beta-cell dysfunction and may synergistically contribute to cerebrovascular injury alongside the MASLD\/FIB-4 phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cross-sectional study enrolled 312 treatment-na\u00efve adults with newly diagnosed T2DM, of whom 278 completed a standardized 75-g oral glucose tolerance test (OGTT; age 24\u201378 years). The primary outcome was ultrasound-confirmed MASLD combined with age-specific FIB-4 screening positivity (age &amp;lt;65 years: FIB-4 \u22651.30; age \u226565 years: FIB-4 \u22652.00). Secondary outcomes included elevated LDL-C (\u22653.4 mmol\/L) and cerebrovascular stenosis (\u226550% luminal narrowing in major intracranial or extracranial arteries).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 199 participants (71.6%) had MASLD and 64 (23.0%) met the primary outcome. Those meeting the primary outcome had significantly higher 1h-PG (17.7\u00a0\u00b1\u00a03.7 vs. 14.9\u00a0\u00b1\u00a03.8 mmol\/L; P&amp;lt;0.001), with an adjusted OR of 1.15 per 1-mmol\/L increment (95% CI 1.05\u20131.26; P\u00a0=\u00a00.003). Elevated LDL-C was present in 73 participants (26.3%) and cerebrovascular stenosis in 49 (17.6%). The composite group of high 1h-PG (\u2265Q3) plus MASLD\/FIB-4 positivity had the highest stenosis rate (34.8% vs. 6.0%), with an adjusted OR of 2.61 (95% CI 1.23\u20135.55; P\u00a0=\u00a00.012). Adding LDL-C attenuated the OR from 3.42 to 2.61 (~24%), indicating partial mediation. The AUC improved from 0.661 (1h-PG alone) to 0.726 (combined model).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In newly diagnosed T2DM, elevated 1h-PG was associated with MASLD\/FIB-4 positivity; their combination was further linked to higher LDL-C and increased cerebrovascular stenosis risk, with LDL-C potentially acting as a partial mediator. The combined model showed improved discriminative ability, though validation in larger multicenter cohorts remains warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1887611","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:31Z","timestamp":1786681411000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of one-hour postload plasma glucose combined with metabolic dysfunction-associated steatotic liver disease and FIB-4 screening positivity with elevated LDL cholesterol and cerebrovascular stenosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Fengtong","family":"Zuo","sequence":"first","affiliation":[{"name":"Department of Cerebrovascular Diseases (Third Division), Cangzhou Central Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoYan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department 2 of Neuroimmunology and Central Nervous System Infection, Cangzhou Central Hospital","place":["Cangzhou, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Tianjin People\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17997","article-title":"A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States","volume":"59","author":"Mittal","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00535-023-02049-9","article-title":"Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography","volume":"59","author":"Kobayashi","year":"2024","journal-title":"J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1499013","article-title":"Non-invasive testing in metabolic dysfunction-associated steatotic liver disease","volume":"11","author":"Dawod","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2337\/db24-0652","article-title":"One-hour postload glucose is a more sensitive marker of impaired beta-cell function than two-hour postload glucose","volume":"74","author":"Lu","year":"2025","journal-title":"Diabetes"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101278","article-title":"Performance of the 1 h oral glucose tolerance test in predicting type 2 diabetes and association with impaired beta-cell function in Asians: a national prospective cohort study","volume":"54","author":"Lee","year":"2025","journal-title":"Lancet Reg Health West Pac"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/11795514251370507","article-title":"Postprandial glucose: a variable in continuum","volume":"18","author":"Joshi","year":"2025","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12902-025-01937-w","article-title":"Association between glucose time-in-range and the severity of metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Endocr Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PloS Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes Facts"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2022.01.007","article-title":"Quantitative ultrasound assessment of hepatic steatosis","volume":"12","author":"Kaliaev","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000609","article-title":"Age-dependent differences in FIB-4 predictions of fibrosis in patients with MASLD referred from primary care","volume":"9","author":"Sung","year":"2025","journal-title":"Hepatol Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"Mozes","year":"2022","journal-title":"Gut"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210391","article-title":"Accuracy of noninvasive scoring systems in assessing liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"16","author":"Han","year":"2022","journal-title":"Gut Liver"},{"key":"B20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2024.00189","article-title":"Advanced liver fibrosis predicts liver outcomes in biopsy-proven metabolic dysfunction-associated steatotic liver disease: a U.S.-based single-center retrospective cohort study","volume":"12","author":"Lam","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10020-024-00905-9","article-title":"Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications","volume":"30","author":"Chen","year":"2024","journal-title":"Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biom15020188","article-title":"A narrative review: relationship between glycemic variability and emerging complications of diabetes mellitus","volume":"15","author":"Wang","year":"2025","journal-title":"Biomolecules"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1042\/CS20257571","article-title":"The physiology of MASLD: molecular pathways between liver and adipose tissues","volume":"139","author":"Lee","year":"2025","journal-title":"Clin Sci (Lond)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14222517","article-title":"Sequential diagnostic approach using FIB-4 and ELF for predicting advanced fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Kang","year":"2024","journal-title":"Diag (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307500","article-title":"Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community","volume":"19","author":"Forlano","year":"2024","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12875-024-02517-y","article-title":"Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems","volume":"25","author":"Kumar","year":"2024","journal-title":"BMC Prim Care"},{"key":"B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2337\/dsi23-0014","article-title":"Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: what clinicians need to know","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","year":"2024","journal-title":"Diabetologia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100424","article-title":"Close multilevel links between metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus","volume":"28","author":"Holleboom","year":"2025","journal-title":"Metab Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaf303","article-title":"Impaired glucagon suppression accompanied by liver fat accumulation mediated worse blood glucose control in patients with T2D","volume":"111","author":"Li","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-3077","article-title":"Increased early postprandial glucagon concentrations in humans with newly diagnosed type 2 diabetes and steatotic liver disease","volume":"49","author":"Huttasch","year":"2026","journal-title":"Diabetes Care"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i22.3548","article-title":"Prospective study comparing hepatic steatosis assessment by magnetic resonance imaging and four ultrasound methods in 105 successive patients","volume":"29","author":"Collin","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2024.0910","article-title":"Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis","volume":"37","author":"Malandris","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020407","article-title":"Diagnostic modalities of non-alcoholic fatty liver disease: from biochemical biomarkers to multi-omics non-invasive approaches","volume":"12","author":"Martinou","year":"2022","journal-title":"Diag (Basel)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31904","article-title":"Methodology exploration and reproducibility evaluation of TAI and TSI for quantitative ultrasound assessment of hepatic steatosis","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng","year":"2024","journal-title":"United Eur Gastroenterol J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1887611\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:32Z","timestamp":1786681412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1887611\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1887611"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1887611","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1887611"}}